Organisation paid for research Program year 2021 Source: CMS Open Payments

Advanced Rheumatology, PC

Neither a doctor nor a teaching hospital

Research payments

$155,013

41 payments

Through program year 2021, Advanced Rheumatology, PC is reported as receiving $155,013 in research payments, across 41 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$9,500	1
2020	Research	$10,088	4
2019	Research	$135,425	36

Breakdown

Who paid Research payments · program years 2019–2021

AbbVie, Inc. $124,387 29 payments
Janssen Research & Development, LLC $13,338 8 payments
Gilead Sciences, Inc. $9,500 1 payment
Celgene Corporation $4,449 1 payment
Amgen Inc. $2,089 1 payment
E.R. Squibb & Sons, L.L.C. $1,250 1 payment

Studies the money was for Research payments · program years 2019–2021

M15-572 $95,312 13 payments
Comparative and Pragmatic Study of Simponi Aria Versus $13,338 8 payments
M15-925 $12,192 7 payments
M13-549 $11,020 5 payments
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy $9,500 1 payment
M14-465 $5,863 4 payments
A phase 3, multicenter, randomized, doubleblind, placebo-controlled, parallel group study, followed by an active-treatment phase to evaluate the efficacy and safety of apremilast (CC-10004) in the treatment of subjects with active behcet s disease (CC-10004-BCT-002) $4,449 1 payment
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. FOREMOST $2,089 1 payment
Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of BMS-986165 in Participants with Systemic Lupus Erythematosus $1,250 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.